325 related articles for article (PubMed ID: 19139332)
1. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
2. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
4. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
Bressler NM; Chang TS; Suñer IJ; Fine JT; Dolan CM; Ward J; Ianchulev T;
Ophthalmology; 2010 Apr; 117(4):747-56.e4. PubMed ID: 20189654
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
[TBL] [Abstract][Full Text] [Related]
8. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
Antoszyk AN; Tuomi L; Chung CY; Singh A;
Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
17. Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration.
Odergren A; Algvere PV; Seregard S; Libert C; Kvanta A
Acta Ophthalmol; 2010 Jun; 88(4):426-30. PubMed ID: 20597872
[TBL] [Abstract][Full Text] [Related]
18. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
Vallance JH; Johnson B; Majid MA; Banerjee S; Mandal K; Bailey CC
Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
[TBL] [Abstract][Full Text] [Related]
19. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]